These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 22083134

  • 1. New horizons for cholesterol ester transfer protein inhibitors.
    Schwartz GG.
    Curr Atheroscler Rep; 2012 Feb; 14(1):41-8. PubMed ID: 22083134
    [Abstract] [Full Text] [Related]

  • 2. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
    Johns DG, Duffy J, Fisher T, Hubbard BK, Forrest MJ.
    Drugs; 2012 Mar 05; 72(4):491-507. PubMed ID: 22356288
    [Abstract] [Full Text] [Related]

  • 3. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
    Mohammadpour AH, Akhlaghi F.
    Clin Pharmacokinet; 2013 Aug 05; 52(8):615-26. PubMed ID: 23658137
    [Abstract] [Full Text] [Related]

  • 4. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
    Shinkai H.
    Vasc Health Risk Manag; 2012 Aug 05; 8():323-31. PubMed ID: 22661899
    [Abstract] [Full Text] [Related]

  • 5. Dalcetrapib: a review of Phase II data.
    Robinson JG.
    Expert Opin Investig Drugs; 2010 Jun 05; 19(6):795-805. PubMed ID: 20465364
    [Abstract] [Full Text] [Related]

  • 6. Cholesteryl ester transfer protein inhibitors in precision medicine.
    Su X, Li G, Deng Y, Chang D.
    Clin Chim Acta; 2020 Nov 05; 510():733-740. PubMed ID: 32941836
    [Abstract] [Full Text] [Related]

  • 7. Trials and Tribulations of CETP Inhibitors.
    Tall AR, Rader DJ.
    Circ Res; 2018 Jan 05; 122(1):106-112. PubMed ID: 29018035
    [Abstract] [Full Text] [Related]

  • 8. [HDL and CETP in atherogenesis].
    Pöss J, Böhm M, Laufs U.
    Dtsch Med Wochenschr; 2010 Feb 05; 135(5):188-92. PubMed ID: 20082258
    [Abstract] [Full Text] [Related]

  • 9. An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels.
    Rhainds D, Arsenault BJ, Brodeur MR, Tardif JC.
    Future Cardiol; 2012 Jul 05; 8(4):513-31. PubMed ID: 22871191
    [Abstract] [Full Text] [Related]

  • 10. Anacetrapib: hope for CETP inhibitors?
    Gurfinkel R, Joy TR.
    Cardiovasc Ther; 2011 Oct 05; 29(5):327-39. PubMed ID: 20406242
    [Abstract] [Full Text] [Related]

  • 11. Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?
    Nurmohamed NS, Ditmarsch M, Kastelein JJP.
    Cardiovasc Res; 2022 Nov 10; 118(14):2919-2931. PubMed ID: 34849601
    [Abstract] [Full Text] [Related]

  • 12. Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events: JACC Review Topic of the Week.
    Armitage J, Holmes MV, Preiss D.
    J Am Coll Cardiol; 2019 Feb 05; 73(4):477-487. PubMed ID: 30704580
    [Abstract] [Full Text] [Related]

  • 13. HDL metabolism and CETP inhibition.
    Barkowski RS, Frishman WH.
    Cardiol Rev; 2008 Feb 05; 16(3):154-62. PubMed ID: 18414186
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of cholesteryl ester transfer protein increases cholesteryl ester content of large HDL independently of HDL-to-HDL homotypic transfer: in vitro vs in vivo comparison using anacetrapib and dalcetrapib.
    Johns DG, Chen Y, Wang SP, Castro-Perez J, Previs SF, Roddy TP.
    Eur J Pharmacol; 2015 Sep 05; 762():256-62. PubMed ID: 26049012
    [Abstract] [Full Text] [Related]

  • 15. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
    Kappelle PJ, van Tol A, Wolffenbuttel BH, Dullaart RP.
    Cardiovasc Ther; 2011 Dec 05; 29(6):e89-99. PubMed ID: 20645987
    [Abstract] [Full Text] [Related]

  • 16. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
    Niesor EJ.
    Curr Opin Lipidol; 2011 Aug 05; 22(4):288-95. PubMed ID: 21587074
    [Abstract] [Full Text] [Related]

  • 17. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
    Briand F, Thieblemont Q, Muzotte E, Burr N, Urbain I, Sulpice T, Johns DG.
    Eur J Pharmacol; 2014 Oct 05; 740():135-43. PubMed ID: 25008069
    [Abstract] [Full Text] [Related]

  • 18. Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention.
    Sirtori CR.
    Expert Opin Investig Drugs; 2011 Nov 05; 20(11):1543-54. PubMed ID: 21961529
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.